<?xml version="1.0" encoding="UTF-8"?>
<p id="Par70">This has led to the recognition that non-HAI or SRH assays need to be taken into account for regulatory approval of next-generation influenza vaccines [
 <xref ref-type="bibr" rid="CR87">87</xref>, 
 <xref ref-type="bibr" rid="CR88">88</xref>], though challenges in standardization of assays and reproducibility between laboratories still need to be overcome. Finally, human challenge trials are gaining acceptance by regulatory agencies for universal vaccine development which may lack traditional serological correlates for protection [
 <xref ref-type="bibr" rid="CR87">87</xref>, 
 <xref ref-type="bibr" rid="CR92">92</xref>â€“
 <xref ref-type="bibr" rid="CR94">94</xref>]. There is increasing recognition that utilizing all aspects of our immune system are needed to control influenza outbreaks.
</p>
